BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28062196)

  • 1. Radiotherapeutic and surgical management of iris melanoma: A review.
    Popovic M; Ahmed IIK; DiGiovanni J; Shields CL
    Surv Ophthalmol; 2017; 62(3):302-311. PubMed ID: 28062196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plaque radiotherapy for residual or recurrent iris melanoma after surgical resection in 32 cases.
    Shah SU; Shields CL; Bianciotto C; Emrich J; Komarnicky L; Shields JA
    Ophthalmology; 2012 Apr; 119(4):838-842.e2. PubMed ID: 22133794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes.
    Shields CL; Shah SU; Bianciotto CG; Emrich J; Komarnicky L; Shields JA
    Ophthalmology; 2013 Jan; 120(1):55-61. PubMed ID: 22980742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications.
    Shields CL; Naseripour M; Shields JA; Freire J; Cater J
    Am J Ophthalmol; 2003 May; 135(5):648-56. PubMed ID: 12719072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton beam radiotherapy of diffuse iris melanoma in 54 patients.
    Willerding GD; Cordini D; Hackl C; Karle B; Lakotka N; Foerster MH; Bechrakis NN; Heufelder J; Moser L; Joussen AM
    Br J Ophthalmol; 2015 Jun; 99(6):812-6. PubMed ID: 25505288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton beam radiotherapy of iris melanoma.
    Damato B; Kacperek A; Chopra M; Sheen MA; Campbell IR; Errington RD
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):109-15. PubMed ID: 16111578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression Patterns of Iris Melanoma after Palladium-103 (
    Chaugule SS; Finger PT
    Ophthalmology; 2017 Jul; 124(7):1023-1030. PubMed ID: 28377036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects.
    Riechardt AI; Klein JP; Cordini D; Heufelder J; Rehak M; Seibel I; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1325-1332. PubMed ID: 29464331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciliary body melanoma with limited nodular extrascleral extension and diffuse iris-angle infiltration treated by whole anterior segment plaque radiotherapy.
    Gray ME; Corrêa ZM; Augsburger JJ; Barrett W
    Int Ophthalmol; 2007 Aug; 27(4):273-6. PubMed ID: 17468833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence of iris melanoma after proton beam therapy.
    Sandinha MT; Kacperek A; Errington RD; Coupland SE; Damato B
    Br J Ophthalmol; 2014 Apr; 98(4):484-7. PubMed ID: 24414401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton beam therapy for iris melanoma: a review of 15 cases.
    Rundle P; Singh AD; Rennie I
    Eye (Lond); 2007 Jan; 21(1):79-82. PubMed ID: 16410818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
    Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
    Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side Effects of Proton Beam Radiotherapy Treatment on Iris Melanoma.
    Eibenberger K; Heimann H; Gatchalian L; Kacperek A; Hussain R
    Ophthalmology; 2023 Sep; 130(9):958-965. PubMed ID: 37169262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Surgical management of iris melanoma].
    Romanowska-Dixon B
    Klin Oczna; 2005; 107(10-12):622-6. PubMed ID: 16619805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anterior plaque brachytherapy placement for treatment of iris and iridociliary melanomas - Surgical procedure and institutional experience.
    Pike S; Engelhard SB; Greig LC; Woods K; Jennelle RL; Berry JL
    Indian J Ophthalmol; 2024 Jun; 72(6):912-915. PubMed ID: 38189366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Ruthenium-106 Brachytherapy for Iris Melanoma: The Scottish Experience.
    Agraval U; Sobti M; Russell HC; Lockington D; Ritchie D; Cauchi P; Kemp EG; Chadha V
    Br J Ophthalmol; 2018 Jan; 102(1):74-78. PubMed ID: 28600302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of non-resectable malignant iris tumours with custom designed plaque radiotherapy.
    Shields CL; Shields JA; De Potter P; Singh AD; Hernandez C; Brady LW
    Br J Ophthalmol; 1995 Apr; 79(4):306-12. PubMed ID: 7742272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifocal iris melanoma in a 2-year-old managed with I-125 plaque brachytherapy.
    Lee AR; Grewal DS; Cummings TJ; Enyedi LB; Larrier NA; Mruthyunjaya P
    J AAPOS; 2017 Oct; 21(5):410-412. PubMed ID: 28844752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of iris melanomas with 125Iodine plaque radiotherapy.
    Fernandes BF; Krema H; Fulda E; Pavlin CJ; Payne DG; McGowan HD; Simpson ER
    Am J Ophthalmol; 2010 Jan; 149(1):70-6. PubMed ID: 19892312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma.
    Tsimpida M; Hungerford J; Arora A; Cohen V
    Eye (Lond); 2011 Dec; 25(12):1607-11. PubMed ID: 21941358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.